In the Magel2-null mouse model, which exhibits features of Prader-Willi syndrome in humans, wild type and Magel2-null mice were treated with placebo (vehicle) or NNZ-2591 for 6 weeks. Treatment with NNZ-2591 normalized fat mass, insulin levels, IGF-1 levels and all behavioural deficits in the Magel2-null mice and had no effect on the wild type mice
Merck to acquire Prometheus in a US$ 10.8 b deal, page-31
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.07 |
Change
-0.400(2.76%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $14.47 | $14.53 | $13.99 | $7.843M | 552.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2150 | $14.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.10 | 1129 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |